Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT04665739 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

NIH

Sponsor class

Conditions

Advanced Lung Neuroendocrine Tumor
Functioning Lung Neuroendocrine Tumor
Locally Advanced Lung Neuroendocrine Neoplasm
Lung Neuroendocrine Neoplasm
Lung Neuroendocrine Tumor G1
Lung Neuroendocrine Tumor G2
Metastatic Lung Neuroendocrine Neoplasm
Metastatic Lung Neuroendocrine Tumor
Non-Functioning Lung Neuroendocrine Tumor
Recurrent Lung Neuroendocrine Neoplasm
Unresectable Lung Neuroendocrine Neoplasm
Unresectable Lung Neuroendocrine Tumor

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Everolimus
OTHER: Fludeoxyglucose F-18
DRUG: Lutetium Lu 177 Dotatate
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
PROCEDURE: Single Photon Emission Computed Tomography
OTHER: Survey Administration

Sponsor

National Cancer Institute (NCI)